Cantor Fitzgerald Comments on Zevra Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for Zevra Therapeutics in a report released on Wednesday, August 14th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of ($1.61) for the year, up from their prior estimate of ($1.68). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.57) per share.

Separately, HC Wainwright increased their target price on Zevra Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $20.25.

Zevra Therapeutics Stock Up 7.2 %

ZVRA opened at $7.59 on Monday. The stock has a market cap of $317.66 million, a PE ratio of -5.62 and a beta of 1.97. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.88. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.44. The business’s fifty day simple moving average is $5.79 and its 200 day simple moving average is $5.54.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. During the same period in the prior year, the company earned ($0.15) EPS.

Insider Activity

In related news, Director Thomas Anderson acquired 10,000 shares of Zevra Therapeutics stock in a transaction dated Tuesday, July 16th. The shares were purchased at an average cost of $6.81 per share, with a total value of $68,100.00. Following the completion of the purchase, the director now owns 20,000 shares of the company’s stock, valued at $136,200. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last three months, insiders have purchased 22,000 shares of company stock valued at $140,340. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Jump Financial LLC bought a new stake in Zevra Therapeutics in the fourth quarter valued at $217,000. Armistice Capital LLC purchased a new position in Zevra Therapeutics during the 4th quarter valued at $1,755,000. Jacobs Levy Equity Management Inc. increased its position in Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after purchasing an additional 17,557 shares during the period. Virtu Financial LLC purchased a new position in Zevra Therapeutics during the 4th quarter valued at $177,000. Finally, Janney Montgomery Scott LLC increased its position in Zevra Therapeutics by 1.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 683,431 shares of the company’s stock valued at $4,476,000 after purchasing an additional 9,062 shares during the period. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.